Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

The Food and Drug Administration has approved Fresenius Kabi's Biologics License Application for the denosumab biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht). These denosumab ...

Generic drugmaker Sandoz (OTCQX:SDZNY) announced Tuesday that the FDA had approved two of its biosimilar products targeting Amgen’s (AMGN) blockbuster bone therapies, Prolia and Xgeva, collectively ...

Findings showed denosumab-qbde demonstrated comparable quality, efficacy, safety, and immunogenicity to the reference product. Enoby is approved to treat postmenopausal women with osteoporosis at high ...

In patients on dialysis, the use of an injectable monoclonal antibody for prevention of osteoporosis-related fractures may increase the risk of MACE compared with oral bisphosphonates, observational ...

Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...